Treatment of autoimmune disease using tolerization in combination with methotrexate
January 23, 2018. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent ReferencesMethod of treating rheumatoid arthritis with type II collagen Treatment of autoimmune diseases by aerosol administration of autoantigens Treatment of autoimmune diseases through administration by inhalation of autoantigens Prevention of autoimmune diseases by aerosol administration of autoantigens Treatment of autoimmune diseases by aerosol administration of autoantigens Method of treating rheumatoid arthritis with soluble collagen Method of treating rheumatoid arthritis with type collagen peptide fragments containing repeating sequences Method of treating rheumatoid arthritis with type II collagen Method of treating rheumatoid arthritis with low dose type II collagen Patent #: 5856446 InventorsAssigneeApplicationNo. 012806 filed on 01/23/1998US Classes:424/184.1, ANTIGEN, EPITOPE, OR OTHER IMMUNOSPECIFIC IMMUNOEFFECTOR (E.G., IMMUNOSPECIFIC VACCINE, IMMUNOSPECIFIC STIMULATOR OF CELL-MEDIATED IMMUNITY, IMMUNOSPECIFIC TOLEROGEN, IMMUNOSPECIFIC IMMUNOSUPPRESSOR, ETC.)424/810, INVOLVING AUTOIMMUNITY, ALLERGY, IMMEDIATE HYPERSENSITIVITY, DELAYED HYPERSENSITIVITY, IMMUNOSUPPRESSION, IMMUNOTOLERANCE, OR ANERGY514/2, Peptide containing (e.g., protein, peptones, fibrinogen, etc.) DOAI514/3, Insulin or derivative514/4, With an additional active ingredient514/21, Produced by or extracted from animal tissue514/249, 1,4-diazine as one of the cyclos514/826, ASTHMA514/866, DIABETES514/885, IMMUNE RESPONSE AFFECTING DRUG514/903MULTIPLE SCLEROSISExaminersPrimary: Saunders, DavidAssistant: VanderVegt, F. Pierre Attorney, Agent or FirmInternational ClassesA61K 039/00A61K 038/17 A61K 038/28 A61K 038/00 AbstractA combination of a mucosally administrable bystander antigen and an orally, enterally, or parenterally administrable methotrexate is employed to make a pharmaceutical formulation and to treat or prevent autoimmune disease. The amounts of bystander antigen and methotrexate are effective in combination to suppress autoimmune response associated with the autoimmune diseaseOther References
Field of SearchANTIGEN, EPITOPE, OR OTHER IMMUNOSPECIFIC IMMUNOEFFECTOR (E.G., IMMUNOSPECIFIC VACCINE, IMMUNOSPECIFIC STIMULATOR OF CELL-MEDIATED IMMUNITY, IMMUNOSPECIFIC TOLEROGEN, IMMUNOSPECIFIC IMMUNOSUPPRESSOR, ETC.)INVOLVING AUTOIMMUNITY, ALLERGY, IMMEDIATE HYPERSENSITIVITY, DELAYED HYPERSENSITIVITY, IMMUNOSUPPRESSION, IMMUNOTOLERANCE, OR ANERGY Peptide containing (e.g., protein, peptones, fibrinogen, etc.) DOAI Insulin or derivative With an additional active ingredient Produced by or extracted from animal tissue ASTHMA DIABETES IMMUNE RESPONSE AFFECTING DRUG MULTIPLE SCLEROSIS | |
